cath.worksCrawled Nov 9, 2026
Landmark ALL-RISE Trial results presented as a LBCT at ACC 2026 and simultaneously published in the New England Journal of Medicine.
The CathWorks FFRangio System gives interventional cardiologists in the cath lab the ability to get more insight with less hassle.
The FAST-FFR pivotal trial was a prospective multicenter, international trial designed to determine the accuracy of FFRangio in clinical practice compared to traditional wire-based FFR. The trial included 301 patients and 319 vessels at 10 clinical sites.
CathWorks provides patient education and patient-friendly information about coronary artery disease (CAD) and how FFRangio works.
The FAME trial compared FFR-guided PCI decision- making (by pressure wire) versus PCI guided by angiography alone in 1,005 randomized patients with multi-vessel coronary artery disease. Routine measurement of FFR significantly reduced clinical events at 1 year.
The FAME Trial’s economic analysis shows that FFR-guided PCI reduces costs and improves health outcomes at one year compared with angiography guidance.
This prospective clinical study conducted at Gifu Heart Centre, Japan—evaluated the diagnostic performance of FFRangio in 50 patients with dual or triple vessel CAD compared to wire-based FFR.
This lesion-level pooled data analysis of 588 patients and 700 lesions represents the “largest and most diverse cohort of any single angiogram-based FFR technology reported.”
CathWorks partners with Quest International to advance cardiovascular disease diagnosis and treatment.
CathWorks announced today key events for the company during the annual American College of Cardiology (ACC) 2023 conference taking place March 4 to 6 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
A schedule of key events for CathWorks during Cardiovascular Research Foundation’s annual Transcatheter Cardiovascular Therapeutics (TCT) 2022 conference.
CathWorks announced today the approval of the fourth generation CathWorks FFRangio System by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
CathWorks offers roles in improving care for patients with coronary artery disease.
CathWorks is dedicated to partnering with physicians to improve the health of patients by transforming how cardiovascular disease is diagnosed and treated.
The CathWorks FFRangio System is available through offices in the United States, Israel, Japan, and the Netherlands.
CathWorks provides grants and sponsorships for academic institutions, medical centers, professional societies, and patient organizations involved in cardiovascular education.
The CathWorks FFRangio System provides cath lab insights with reduced complexity.
CathWorks FFRangio System is a quick, reliable intraprocedural physiologic assessment for the entire coronary tree.
CathWorks Inc. and CathWorks Ltd. protect user privacy as outlined in their Privacy Policy.
